12th January 2022 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full-service finance company for Life Sciences, Clean and Deep Tech companies, has expanded its portfolio with the launch of three new products: the Incubator, Seed and Series packages. The company has also expanded its CFO Services to include Partnering and M&A Services, and Fundraising Services. These products emphasize F.INSTITUTE’s ambition to become the European one-stop market leader for financial services for start-ups and scale-ups.
News
After 15 years in Biotech Tom Froggatt set up Singular Talent to help Biotech companies engage, attract and secure the talent they need and to make the hiring experience better from both sides of the table. He revealed how the values that are the bedrock of the company and .... much more:
Why I started Singular Talent
Fremont, CA, US and Cambridge, UK – 04 January 2022 – Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.
MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years.
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein.
• UK CFOs focused on business expansion in 2022
• Record* number of CFOs say increasing capital investment is a strong priority for their business in the year ahead
• Overwhelming majority of CFOs expect greater investment in digital technology and workforce skills over the next three years
• Despite rising inflation and the emergence of the Omicron variant, CFO risk appetite has nudged higher
• CFOs expect productivity to grow faster in the next three years, than in the years before the pandemic
Cambridge, UK and Durham, NC, USA, 05 January 2022: PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, today announced a collaboration to study oncology targets currently considered undruggable.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration.
Innovate UK, the National Institute of Health Research (NIHR; i4i programme and AI in Health and Care Award) and the Small Business Research Initiative (SBRI) Healthcare have joined forces to offer specialist support to companies within their portfolios, from across the UK, via their Investment Readiness Programme. The programme will support selected companies to gain additional skills and expertise to get them prepared to find and attract investment.